Acorda Therapeutics, Inc.

OTCPK:ACOR.Q 株式レポート

時価総額:US$320.5k

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Acorda Therapeutics マネジメント

マネジメント 基準チェック /24

Acorda Therapeutics'の CEO はRon Cohenで、 Jan1995年に任命され、 の在任期間は 29.42年です。 の年間総報酬は$ 996.33Kで、 62.7%給与と37.3%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.6%を直接所有しており、その価値は$ 1.95K 。経営陣と取締役会の平均在任期間はそれぞれ6.1年と21年です。

主要情報

Ron Cohen

最高経営責任者

US$996.3k

報酬総額

CEO給与比率62.7%
CEO在任期間29.4yrs
CEOの所有権0.6%
経営陣の平均在職期間6.1yrs
取締役会の平均在任期間21yrs

経営陣の近況

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26
Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

Recent updates

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Feb 21
Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Dec 18
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Jun 05
Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Oct 17

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Oct 10

Acorda inks license deal with Asieris for pre-clinical drug

Aug 29

Acorda Therapeutics announces resignation of COO

Aug 19

Acorda Therapeutics: Managing The Transition

Oct 04

Acorda Therapeutics Continues To Maneuver For A Turnaround

Jul 24

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Jun 17

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26
Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Mar 09
Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Acorda Therapeutics to sell Inbrija manufacturing operations for $80M, reduces headcount by 16%, shares up 65%

Jan 13

What Kind Of Investors Own Most Of Acorda Therapeutics, Inc. (NASDAQ:ACOR)?

Jan 04
What Kind Of Investors Own Most Of Acorda Therapeutics, Inc. (NASDAQ:ACOR)?

Acorda Therapeutics completes 1-for-6 reverse stock split

Dec 31

Acorda Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 05

CEO報酬分析

Acorda Therapeutics の収益と比較して、Ron Cohen の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$263m

Dec 31 2023US$996kUS$625k

-US$253m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$58m

Dec 31 2022US$984kUS$625k

-US$66m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$119m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$2mUS$743k

-US$104m

Sep 30 2021n/an/a

-US$166m

Jun 30 2021n/an/a

-US$132m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$2mUS$796k

-US$100m

Sep 30 2020n/an/a

US$49m

Jun 30 2020n/an/a

-US$222m

Mar 31 2020n/an/a

-US$232m

Dec 31 2019US$2mUS$796k

-US$273m

Sep 30 2019n/an/a

-US$329m

Jun 30 2019n/an/a

-US$79m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$2mUS$796k

US$34m

Sep 30 2018n/an/a

-US$147m

Jun 30 2018n/an/a

-US$158m

Mar 31 2018n/an/a

-US$213m

Dec 31 2017US$2mUS$792k

-US$223m

報酬と市場: Ronの 総報酬 ($USD 996.33K ) は、 US市場 ($USD 667.63K ) の同規模の企業の平均を上回っています。

報酬と収益: Ronの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Ron Cohen (68 yo)

29.4yrs

在職期間

US$996,328

報酬

Dr. Ron Cohen, M.D., serves as an Independent Director of ZWI Therapeutics, Inc. since January 2024. He has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Ron Cohen
Founder29.4yrsUS$996.33k0.60%
$ 1.9k
Michael Gesser
CFO & Treasurer2.6yrsUS$611.55k0%
$ 0
Neil Belloff
General Counsel & Corporate Secretary2.6yrsUS$661.57k0%
$ 0
Denise Duca
Executive Vice President of Human Resources9.4yrsデータなしデータなし
Kerry Clem
Chief Commercial Officer2.8yrsUS$592.23k0.041%
$ 130.0
Sofia Ali
Senior VP of Operations & Strategic Planningno dataデータなしデータなし
Susan Way
Senior VP of Drug Development & Regulatory Affairsno dataデータなしデータなし
Wise Young
Special Scientific Advisorno dataUS$10.00kデータなし

6.1yrs

平均在職期間

64yo

平均年齢

経験豊富な経営陣: ACOR.Qの経営陣は経験豊富で経験豊富です(平均在職期間は6.1年)。


取締役

名称ポジション在職期間報酬所有権
Ron Cohen
Founder29.4yrsUS$996.33k0.60%
$ 1.9k
John Varian
Independent Director2.4yrsUS$94.71k0%
$ 0
Carl Cotman
Member of Scientific Advisory Boardno dataデータなしデータなし
Sandra Panem
Independent Director26.4yrsUS$82.65k0.0019%
$ 6.2
Mark Tuszynski
Member of Scientific Advisory Boardno dataデータなしデータなし
Melitta Schachner
Member of Scientific Advisory Boardno dataデータなしデータなし
Patrick Tresco
Member of Scientific Advisory Boardno dataデータなしデータなし
Stephen Waxman
Member of Scientific Advisory Boardno dataデータなしデータなし
Mary Bunge
Member of Scientific Advisory Boardno dataデータなしデータなし
James Fawcett
Member of Scientific Advisory Boardno dataデータなしデータなし
Michael Beattie
Member of Scientific Advisory Boardno dataデータなしデータなし
John Kelley
Independent Non-Executive Chairman15.5yrsUS$140.22k0%
$ 0

21.0yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: ACOR.Qの 取締役会 は経験豊富で 経験豊富 です ( 21年の平均在任期間)。